Cidelon

INSTRUCTIONS FOR MEDICAL USE OF THE MEDICINAL PRODUCT CYDELON (CIDELON)

Composition:

Active substances: zinc sulfate, decamethoxine;

1 ml of solution contains zinc sulfate 2.5 mg; decamethoxine 0.2 mg;

Excipients: sodium chloride, methylcellulose, purified water.

Pharmaceutical form. Eye drops.

Main physicochemical characteristics: colorless, clear or slightly opalescent liquid.

Pharmacotherapeutic group. Agents for ophthalmological use. Antimicrobial agents. ATC code S01AX03.

Pharmacological properties.

Pharmacodynamics.

A combined preparation for topical use. Exerts antiseptic, anti-allergic, and anti-inflammatory effects. Zinc sulfate, when applied topically, exerts antiseptic, astringent, drying, and local anti-inflammatory actions.

Decamethoxine exerts an antiseptic effect and has a broad antimicrobial spectrum of activity against gram-positive (staphylococci, pneumococci, streptococci) and gram-negative (gonococci, meningococci) cocci, corynebacteria, gram-negative bacteria (enterobacteria, pseudomonads), protozoa, dermatophytes, Candida species yeasts, chlamydia, and viruses. During application of Cidelon, resistant variants of microorganisms develop slowly. The preparation potentiates the effect of conventional antimicrobial agents in combined therapy.

Pharmacokinetics.

Not studied.

Clinical characteristics.

Indications.

Inflammatory diseases of the anterior segment of the eye of microbial etiology (keratitis, keratoconjunctivitis), as well as inflammatory reactions of the conjunctiva following surgical procedures.

Contraindications.

Hypersensitivity to the components of the medicinal product. Children under 12 years of age.

Interaction with other medicinal products and other forms of interaction.

Do not use together with other ophthalmic preparations.

Instructions for use.

After opening, close the bottle with the dropper cap.

The medication should not be used during contact lens wear.

Use during pregnancy or breastfeeding.

As there is no experience with the use of the drug in pregnant women or women who are breastfeeding, the benefit-risk ratio should be considered before prescribing the drug.

Ability to affect reaction speed when driving or operating machinery.

Patients who experience blurred vision after instillation of the drug should refrain from driving or operating machinery.

Method of Administration and Dosage.

Administer the drug to adults and children aged 12 years and older, 1–2 drops 3 times daily into the affected eye. The duration of treatment is determined by the physician depending on the severity and course of the disease: usually until complete disappearance of symptoms.

Children.

Do not use in children under 12 years of age.

Overdose.

Cases of overdose have not been observed.

Side effects.

Hypersensitivity reactions are possible in cases of increased sensitivity to the components of the drug. Local reactions at the site of application are also possible.

Shelf life. 3 years.

The shelf life of the solution after opening the bottle is 14 days.

Storage conditions. Store in the original packaging at a temperature not exceeding 25 °C.

Keep out of reach of children.

Packaging. 5 ml or 10 ml in a bottle with a dropper cap in a carton.

Prescription status. Prescription only.

Manufacturer.

Limited Liability Company "Experimental Plant "GNCLS".

Limited Liability Company "FARMEKS GROUP".

Manufacturer's location and address of business activity.

8 Vorobiova Street, Kharkiv, Kharkiv Region, 61057, Ukraine.

(Limited Liability Company "Experimental Plant "GNCLS")

100 Shevchenka Street, Boryspil, Kyiv Region, 08301, Ukraine.

(Limited Liability Company "FARMEKS GROUP")